Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Division of Inpatient Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer. 2021 Mar 15;127(6):875-883. doi: 10.1002/cncr.33344. Epub 2020 Nov 25.
Brief measures of physical function such as gait speed may be useful to optimize treatment intensity for older adults who have blood cancer; however, little is known about whether such assessments are already captured within oncologists' "gestalt" assessments.
Gait speed was assessed in 782 patients ≥75 years of age who had blood cancer, with results reported to providers after treatment decisions were made; 408 patients required treatment when different intensities were available per National Comprehensive Cancer Network (NCCN) guidelines. We performed structured abstractions of treatment intensity recommendations into standard intensity, reduced intensity, or supportive care, based on NCCN guidelines. We modeled gait speed and survival using Cox regression and performed ordinal logistic regression to assess predictors of NCCN-based categorizations of oncologists' treatment intensity recommendations, including gait speed.
The median survival by gait speed category was 10.8 months (<0.4 m/s), 18.6 months (0.4-0.6 m/s), 34.0 months (0.6-0.8 m/s), and unreached (>0.8 m/s). Univariable hazard ratios (HRs) for death increased for each lower category compared with ≥0.8 m/s (0.6-0.8 m/s: HR, 1.76; 0.4-0.6 m/s: HR, 2.30; <0.4 m/s: HR, 3.31). Gait speed predicted survival in multivariable Cox regression (all P < .05). In multivariable models including age, sex, and Eastern Cooperative Oncology Group performance status, gait speed did not predict oncologists' recommended treatment intensity (all P > .05) and did not add to a base model predicting recommended treatment intensity.
In older adults with blood cancer who presented for treatment, gait speed predicted survival but not treatment intensity recommendation. Incorporating gait speed into decision making may improve optimal treatment selection.
对于患有血液癌的老年人,简要的身体功能评估(如步态速度)可能有助于优化治疗强度;然而,关于这些评估是否已经被肿瘤学家的“整体评估”所包含,知之甚少。
评估了 782 名年龄在 75 岁以上患有血液癌的患者的步态速度,在治疗决策做出后向提供者报告结果;根据国家综合癌症网络(NCCN)指南,408 名患者需要治疗,且有不同的治疗强度。我们根据 NCCN 指南将治疗强度建议的结构化摘要分为标准强度、降低强度或支持性护理。我们使用 Cox 回归模型对步态速度和生存进行建模,并进行有序逻辑回归以评估肿瘤学家治疗强度建议的 NCCN 分类的预测因素,包括步态速度。
按步态速度分类的中位生存时间分别为<0.4 m/s(10.8 个月)、0.4-0.6 m/s(18.6 个月)、0.6-0.8 m/s(34.0 个月)和>0.8 m/s(未达到)。与≥0.8 m/s 相比,每个较低的类别死亡的风险比(HR)均增加(0.6-0.8 m/s:HR,1.76;0.4-0.6 m/s:HR,2.30;<0.4 m/s:HR,3.31)。步态速度在多变量 Cox 回归中预测生存(均 P<0.05)。在包括年龄、性别和东部肿瘤协作组表现状态的多变量模型中,步态速度未预测肿瘤学家推荐的治疗强度(均 P>0.05),且未增加预测推荐治疗强度的基础模型。
在患有血液癌并接受治疗的老年患者中,步态速度预测生存,但不能预测治疗强度建议。将步态速度纳入决策可能会改善最佳治疗选择。